UVaCide raises $6 million in financing

UVaCide was formed in 2004 to develop a series of medical technology solutions utilizing next generation laser technologies. After years of comprehensive research into various light-based solutions, UVaCide said that it is currently poised to release its first laser solution for commercial use – a solution that addresses toenail fungus.

John Strisower, founder and CEO of UVaCide, said: “Nexus has extensive experience assisting emerging medical technology companies like UVaCide. Their willingness to become a significant investor in UVaCide provides an endorsement of our technology that we believe speaks for itself. Their experience and leadership will be instrumental as we begin the revenue acquisition/market acquisition stage of our business development.”